Literature DB >> 6661732

Disposition of mitoxantrone in patients.

D S Alberts, Y M Peng, S Leigh, T P Davis, D L Woodward.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6661732     DOI： 10.1016/0305-7372(83)90018-x

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  10 in total

Review 1.  Mass balance studies, with a focus on anticancer drugs.

Authors:  Jan H Beumer; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Effectiveness of mitoxantrone on the proliferation of cell cultures derived from malignant mesenchymal tumors of human origin.

Authors:  M Dietel; H Arps; D Gerding; M Trapp; M Sieck; A Niendorf
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

3.  A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding.

Authors:  Guohua An; Marilyn E Morris
Journal:  AAPS J       Date:  2012-03-27       Impact factor: 4.009

4.  Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration.

Authors:  J D Nagel; F J Varossieau; R Dubbelman; W W ten Bokkel Huinink; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 5.  Pharmacokinetics and metabolism of mitoxantrone. A review.

Authors:  G Ehninger; U Schuler; B Proksch; K P Zeller; J Blanz
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

6.  Pharmacology of mitoxantrone: mode of action and pharmacokinetics.

Authors:  D S Alberts; Y M Peng; G T Bowden; W S Dalton; C Mackel
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

7.  Comparative in vitro toxicity of mitoxantrone and adriamycin in human granulocyte-macrophage progenitor cells.

Authors:  H G Mergenthaler; P Brühl; G Ehninger; E Heidemann
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

8.  The pharmacokinetics and metabolism of mitoxantrone in man.

Authors:  G Ehninger; B Proksch; G Heinzel; E Schiller; K H Weible; D L Woodward
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

9.  Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy.

Authors:  S J Van Belle; M M de Planque; I E Smith; A T van Oosterom; T J Schoemaker; W Deneve; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation.

Authors:  B Richard; M C Launay-Iliadis; A Iliadis; S Just-Landi; D Blaise; A M Stoppa; P Viens; M H Gaspard; D Maraninchi; J P Cano
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.